From amfar wiki page: https://en.m.wikipedia.or
Post# of 148294
https://en.m.wikipedia.org/wiki/AmfAR,_The_Fo...S_Research
National initiatives: ...
In November 2020, amfAR signed an agreement with CytoDyn Inc. to explore the potential of its CCR-5 antagonist Vyrologix (Leronlimab) to mediate a functional HIV cure. According to Kevin Robert Frost, Chief Executive Officer at amfAR, "demonstrating that Leronlimab can functionally phenocopy CCR5 deficiency and replicate the London and Berlin patients would be a major advancement.”[61]